Want to see PLRX full AI Analyst Report?
PLRX Stock Chart & Stats
$1.33
-$0.35(-2.64%)
At close: 4:00 PM EST
$1.33
-$0.35(-2.64%)
Day’s Range― - ―
52-Week Range$1.07 - $1.95
Previous CloseN/A
Volume34.91K
Average Volume (3M)581.13K
Market Cap
$71.21M
Enterprise Value-$64.24
Total Cash (Recent Filing)$170.89M
Total Debt (Recent Filing)$28.78M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 10, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding61,920,250
10 Day Avg. Volume902,150
30 Day Avg. Volume581,135
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-0.58
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$2.67Price Target Upside100.50% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-1.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
R&D Governance StrengthenedAdding two independent directors with scientific credentials and placing them on the R&D committee (one as chair) increases technical oversight and strategic guidance. This durable governance improvement can raise trial design quality, regulatory preparedness, and partner confidence, improving long-term execution of the pipeline.
Improving Cash Burn TrendSequential reductions in negative free cash flow signal better cost discipline or program prioritization. A sustained decline in burn-rate lengthens runway and reduces near-term financing pressure, improving the firm’s ability to advance lead programs without immediate dilution if trend continues.
Low Financial LeverageRelatively low debt for a development-stage biotech keeps interest obligations limited and preserves financial flexibility. Manageable leverage reduces refinancing risk and supports the company's ability to raise capital or enter collaborations without the constraints of heavy fixed payments.
Bears Say
No Commercial RevenueAbsence of product revenue leaves the company fully dependent on development progress and external funding. This structural lack of recurring income increases execution risk, limits visibility into sustainability, and makes long-term operations contingent on successful clinical outcomes or partner deals.
Shrinking Equity BaseA materially smaller equity cushion reduces balance-sheet flexibility and increases vulnerability to adverse outcomes. Persistent losses that erode shareholders' equity raise the likelihood that management will need dilutive financing, constraining strategic options and investor recovery in downside scenarios.
Ongoing Reliance On External FundingSustained negative operating and free cash flow means future R&D and trials depend on capital markets, partner financing, or asset sales. This structural funding dependence exposes the company to market conditions and dilution risk, which can limit long-term strategic autonomy and investment pacing.
Pliant Therapeutics News
PLRX FAQ
What was Pliant Therapeutics’s price range in the past 12 months?
Pliant Therapeutics lowest stock price was $1.07 and its highest was $1.95 in the past 12 months.
What is Pliant Therapeutics’s market cap?
Pliant Therapeutics’s market cap is $71.21M.
When is Pliant Therapeutics’s upcoming earnings report date?
Pliant Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 20 days.
How were Pliant Therapeutics’s earnings last quarter?
Pliant Therapeutics released its earnings results on May 11, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.357 by $0.037.
Is Pliant Therapeutics overvalued?
According to Wall Street analysts Pliant Therapeutics’s price is currently Undervalued.
Does Pliant Therapeutics pay dividends?
Pliant Therapeutics does not currently pay dividends.
What is Pliant Therapeutics’s EPS estimate?
Pliant Therapeutics’s EPS estimate is -0.34.
How many shares outstanding does Pliant Therapeutics have?
Pliant Therapeutics has 61,920,250 shares outstanding.
What happened to Pliant Therapeutics’s price movement after its last earnings report?
Pliant Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.357. Following the earnings report the stock price went down -1.667%.
Which hedge fund is a major shareholder of Pliant Therapeutics?
Currently, no hedge funds are holding shares in PLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pliant Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.67 (100.50% Upside)
$2.67 (100.50% Upside)
Hedge Fund Trend
Decreased
By 359.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-89.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-41.24%
Trailing 12-Months
Company Description
Pliant Therapeutics
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
PLRX Stock 12 Month Forecast
Average Price Target
$2.67
▲(100.50% Upside)
Technical Analysis
Ownership Overview
2.48% Insiders
6.05% Mutual Funds
0.44% Other Institutional Investors
86.46% Public Companies and
Individual Investors